SCHEMBL25318673

SCHEMBL25318673

CC(C)(C)OC(=O)N1CCC(O)(c2ccc(N3CCCC3)nc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.47
CRBN Q96SW2 1/20 0.47
CKS1B P61024 2/20 0.47
SKP1 P63208 2/20 0.47
SKP2 Q13309 2/20 0.47
GPR119 Q8TDV5 4/20 0.47
MAP4K4 O95819 1/20 0.43
PIK3CD O00329 1/20 0.43
RET P07949 6/20 0.42
ADK P55263 1/20 0.41
OGA O60502 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
WNT3A P56704 1/20 0.41
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475514 1.00 DDB1 (0.47) DDB1CRBNCKS1BSKP1SKP2
SCHEMBL28406959 0.90 DDB1 (0.50) DDB1CRBNCKS1BSKP1SKP2
SCHEMBL25322835 0.83 GPR119 (0.48) CKS1BSKP1SKP2GPR119MAP4K4
SCHEMBL31314534 0.82 NAMPT (0.45) CKS1BSKP1SKP2MAP4K4JAK2
SCHEMBL12453384 0.82 NAMPT (0.45) CKS1BSKP1SKP2MAP4K4JAK2
SCHEMBL29980884 0.82 OPRD1 (0.42) CKS1BSKP1SKP2GPR119OPRD1
SCHEMBL12489219 0.82 OPRD1 (0.42) CKS1BSKP1SKP2GPR119OPRD1
SCHEMBL19491057 0.82 OPRD1 (0.42) CKS1BSKP1SKP2GPR119OPRD1
SCHEMBL2884922 0.82 JAK2 (0.46) CKS1BSKP1SKP2GPR119JAK2
SCHEMBL29475511 0.82 JAK2 (0.46) CKS1BSKP1SKP2GPR119JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107759563-B Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate 上海再启生物技术有限公司 2020-06-02 CN claimed
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. 2024-02-08 US disclosed
EP-4217342-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING Neuropore Therapies, Inc. (US) 2023-08-02 EP disclosed
CN-116507607-A Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2023-07-28 CN disclosed
CN-107759563-B Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate 上海再启生物技术有限公司 2020-06-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 DDB1 2027/4885CRBN 1677/4885CKS1B 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.